Study guide
14.2 Heart Failure Phenotype, Acuity, and Hypertensive Combinations
AHIMA Certified Documentation Integrity Practitioner CDIP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Authoritative Coding Resources & Conventions
1.1 Official Coding Resources: Scope, Authority & Research 1.2 General Coding Conventions, Punctuation & Instructional Notes 1.3 Chapter-Specific and Setting-Specific Coding Guidelines
2 Chapter 2: Principal & Secondary Diagnosis Determination
2.1 UHDDS Definitions & Principal Diagnosis Selection 2.2 Two or More Diagnoses Equally Meeting Criteria 2.3 Secondary Diagnosis Reporting Standards & POA Status
3 Chapter 3: Procedure Coding & Sequencing Standards
3.1 ICD-10-PCS Root Operations & Inpatient Procedure Coding 3.2 Principal Procedure Selection & Surgical Sequencing 3.3 Applying Official References to Ambiguous Records
4 Chapter 4: Inpatient Prospective Payment & DRG Grouping
4.1 MS-DRG Logic, CC/MCC Exclusions & Severity Levels 4.2 Working vs. Final DRG Assignment & Optimization vs. Maximization 4.3 CDI-Coding Reconciliation & Annual Regulatory Updates
5 Chapter 5: Enterprise CDI Promotion & Program Value
5.1 Articulating CDI Value to C-Suite & Hospital Leadership 5.2 Organizational Models, Inpatient/Outpatient Scope & Staffing 5.3 Cross-Functional Collaboration: HIM, Quality & Case Management
6 Chapter 6: Cross-Functional Alignment & Improvement Projects
6.1 Partnering with Nursing, Pharmacy & Allied Health Professionals 6.2 Documentation Improvement Project Identification & Scoping 6.3 Executing, Piloting & Measuring CDI Project Outcomes
7 Chapter 7: Physician Champion Engagement & Clinical Advocacy
7.1 Selection, Role & Credibility of the CDI Physician Champion 7.2 Peer-to-Peer Engagement, Coaching & Overcoming Resistance 7.3 Developing Standard CDI Operational Policies & Procedures
8 Chapter 8: Compliant Policy Architecture & Query Governance
8.1 AHIMA/ACDIS Practice Brief Standards in Policy Construction 8.2 Medical Record Integration of Provider Query Responses 8.3 Policies for Electronic, Paper, and Verbal Query Communications
9 Chapter 9: Query Escalation & Professional Communication
9.1 Chain of Command & Protocols for Unanswered Queries 9.2 Conflict Resolution & Professional Feedback Mechanisms 9.3 Assessing Stakeholder Learning Needs & Specialty Curricula
10 Chapter 10: Educational Delivery & Broader Healthcare Impacts
10.1 Delivery Methods: Microlearning, Case Studies & Grand Rounds 10.2 Documentation Impacts on Clinical Research & Epidemiology 10.3 Documentation Impacts on Case Management, LOS & Reimbursement
11 Chapter 11: Clinical Record Synthesis & Encounter Trajectory
11.1 Synthesizing Provider Notes, Consults & Progress Trajectory 11.2 Interpreting Diagnostic Imaging, Pathology & Labs 11.3 Resolving Conflicting, Ambiguous & Copy-Forward Entries
12 Chapter 12: Advanced Clinical Concepts & Review Prioritization
12.1 Pharmacotherapy, Clinical Trajectories & Disease Correlations 12.2 Inpatient Review Prioritization: High-Risk & High-Volume 12.3 Payer Prioritization, Length of Stay & Re-Review Cadence
13 Chapter 13: Clinical Indicator Mapping & Gap Recognition
13.1 Systematic Identification of Documentation Gaps 13.2 Sepsis Definitions, SEP-1, and Coding 13.3 AKI Criteria, Tubular Injury, and CKD Staging
14 Chapter 14: Diagnostic Precision in High-Impact Conditions
14.1 Respiratory Failure: Acuity, Evidence, and Sequencing 14.2 Heart Failure Phenotype, Acuity, and Hypertensive Combinations 14.3 Encephalopathy, Delirium, and Acute Cognitive Change
15 Chapter 15: Clinical Validation & Complication Discrepancies
15.1 Malnutrition Assessment, Severity, and Provider Documentation 15.2 Principles of a Compliant, Nonleading Query 15.3 Open-Ended, Multiple-Choice, and Yes/No Queries
16 Chapter 16: Query Mechanics & Direct Provider Collaboration
16.1 Electronic Query Systems, Templates, and Technology Oversight 16.2 Collaborating With the Appropriate Query Recipient 16.3 Capturing and Clarifying Query Responses
17 Chapter 17: Quality Indicators & Post-Discharge Clarification
17.1 Present on Admission Clarification and Selected HAC Rules 17.2 Clarifying Acuity, Cause, Site and Severity 17.3 Post-Discharge Query Opportunities and Limits 17.4 Managing Post-Discharge Query Workflows
18 Chapter 18: CDI Operational Dashboards & Quality Auditing
18.1 Departmental Metrics: Definitions, Calculations and Dashboard Use 18.2 Internal CDI Quality Audits and Reviewer Calibration 18.3 Query Trends: Understanding the Process and Provider Experience
19 Chapter 19: Benchmarking, Productivity & Data-Driven Workflow
19.1 Provider Documentation Benchmarking 19.2 External Benchmarking: CMI, Severity, Mortality and Length of Stay 19.3 Evaluating CDI Professional Performance 19.4 Using Data to Design CDI Workflow and Staffing
20 Chapter 20: Ethical CDI Standards & Regulatory Frameworks
20.1 Applying AHIMA Ethics to CDI Decisions 20.2 Responding to Financial Pressure and Upcoding Risks 20.3 Maintaining Competence and Professional Integrity
21 Chapter 21: Regulatory Compliance & Enforcement Landscapes
21.1 False Claims, Overpayments and Referral Laws 21.2 Regulatory Agencies, Review Contractors and Appeals 21.3 EHR Templates, Copied Text and Record Integrity
22 Chapter 22: Technology Risks & Second-Level Review Protocols
22.1 CAC, NLP and AI: Context, Oversight and Performance 22.2 Selecting Cases for Second-Level Review 22.3 Conducting and Closing a Second-Level Review
23 Chapter 23: Clinical Validation Queries & Risk Mitigation
23.1 Clinical Validation and Coding Clarification 23.2 Clinical Validation Queries and Denial Evidence 23.3 Detecting Leading, Biased and Unsupported Queries
24 Chapter 24: Noncompliant Query Remediation & Query Lifecycle Management
24.1 Query Remediation and Corrective Action 24.2 Query Timeframes, Aging and Measurement 24.3 Query Records, Retention and Evidence Preservation
14.2 Heart Failure Phenotype, Acuity, and Hypertensive Combinations
Key Takeaways Explain This Topic AI
The 2022 AHA/ACC/HFSA framework includes HFrEF, HFmrEF, HFpEF and HFimpEF; EF alone does not establish the complete diagnosis or its acuity.
The Index recognizes documented HFrEF/HFpEF terminology. Use the full diagnostic phrase and applicable decompensation/combined-failure paths rather than coding a raw echo percentage.
In final MS-DRG v44, acute and acute-on-chronic systolic, diastolic and combined HF codes in the lesson table are MCCs; their chronic counterparts are CCs, subject to exclusions.
Hypertension relationships remain presumed unless documentation indicates nonrelationship. Qualifying heart disease with CKD can require I13 and additional I50/N18 codes; hypertension with CKD alone is a different pathway.
BNP, imaging, diuretics and response support clinical assessment but do not establish a universal phenotype, acuity, or reimbursement outcome.
Last updated: October 2026
Heart failure: phenotype, acuity, and associated conditions
Heart-failure review begins with the clinician's diagnosis and the patient's course. Keep three questions separate: what heart-failure phenotype is documented, whether an acute component is present, and which associated-condition instructions apply . An ejection fraction, natriuretic peptide, or diuretic order contributes evidence but does not independently answer all three questions.
The purpose of clarification is an accurate description of illness. “CHF” remains a recognized Index term; it is not prohibited or automatically false. Greater specificity can improve the record when supported, but a query must permit the provider to reach the clinically appropriate conclusion, including uncertainty.
Clinical EF categories are not the whole diagnosis
The 2022 AHA/ACC/HFSA guideline's official slide set distinguishes these clinical categories:
- Category EF-based description Context that matters
- HFrEF LVEF at most 40% Interpret within the established HF diagnosis
- HFmrEF LVEF 41–49% The framework also requires evidence of increased LV filling pressures
- HFpEF LVEF at least 50% The framework also requires evidence of increased LV filling pressures
HFimpEF Previous LVEF at most 40%, followed by LVEF above 40% Preserve the prior measurements and clinical trajectory
Evidence of increased filling pressures can be spontaneous or provoked and may involve natriuretic peptides, imaging, or invasive measurements. A normal-range EF alone does not establish HFpEF; conversely, it does not exclude heart failure. The clinical history, symptoms, examination, and further assessment matter.
EF category also does not determine acuity. A patient with chronically reduced EF can be stable, and a patient with preserved EF can develop acute decompensation. A follow-up EF above 40% after prior HFrEF should not automatically be relabeled new diastolic failure merely because the number improved. Ask about the intended diagnosis when the documentation and history leave a meaningful ambiguity.
The Index recognizes HF with reduced EF under the systolic pathway and HF with preserved or normal EF under the diastolic pathway. These are documented diagnostic terms; CDI need not require a second synonym simply to duplicate an already clear diagnosis. Clinical terms such as HFmrEF or HFimpEF require attention to the complete provider description and applicable Index path rather than a reviewer converting a percentage into systolic, diastolic, or combined failure.
Combined systolic and diastolic failure is also a recognized category. The FY 2027 Tabular List includes heart failure with reduced EF and diastolic dysfunction under I50.4-. Check the actual diagnostic wording and Index route; do not independently construct combined heart failure from an echo's numerical or descriptive findings alone.
Establish the acute component from the course
Review the baseline symptoms and function, the reason for presentation, evidence of congestion or impaired perfusion, actual interventions, and the provider's assessment. Findings such as new orthopnea, pulmonary congestion, edema, weight change, or worsening function can support evaluation. They do not all have to appear in every case, and each has alternative explanations.
Compare the admission course with the established baseline. “Acute” and “acute on chronic” are not interchangeable. An old HF diagnosis, current treatment, and a new symptom do not authorize the reviewer to choose an acuity without interpreting the actual documented assessment.
The Index contains additional instructions for decompensated HF. For example, the heart-failure entry directs decompensated systolic and diastolic terms to their acute-and-chronic pathways; unqualified heart failure with decompensation remains I50.9 in that entry. Do not impose a universal rule that every use of “decompensated” means only acute HF, or that it supplies a missing systolic/diastolic subtype. Follow the full documented phrase and clarify genuine inconsistency.
Use biomarkers and treatment as evidence
BNP or NT-proBNP can support diagnostic evaluation. The AHA guideline also lists other reasons for elevated values, including atrial fibrillation, advancing age, renal failure, pulmonary embolism, and critical illness. The ACC's 2023 HFpEF consensus notes that natriuretic peptide levels can be lower in obesity. An isolated high value therefore does not prove acute HF, while a relatively low value does not settle every HFpEF assessment.
Imaging may show congestion or structural abnormalities, but a pleural effusion or enlarged heart alone does not establish a specific acute phenotype. Preserve the report and the provider's interpretation instead of replacing them with the reviewer's conclusion.
Loop-diuretic administration and response can help explain the clinical course, but treatment is not exclusive to one cause of edema. Check what was actually administered, its indication, and any held or discontinued orders. There is no universal dose, infusion requirement, or peptide cutoff that independently establishes an acute systolic, diastolic, or combined diagnosis for coding.
Apply the actual code and severity distinctions
FY 2027 I50 distinguishes systolic, diastolic, and combined failure, with separate acute, chronic, acute-on-chronic, and unspecified-acuity codes. Final MS-DRG v44 Appendix C identifies these secondary-diagnosis classifications:
- Documented type Acute Chronic Acute on chronic
- Systolic I50.21: MCC I50.22: CC I50.23: MCC
- Diastolic I50.31: MCC I50.32: CC I50.33: MCC
- Combined systolic and diastolic I50.41: MCC I50.42: CC I50.43: MCC
Thus, acute diastolic failure is not a CC in this version. Verify the exact code and version instead of assuming every diastolic code has the same status.
I50.9 is heart failure, unspecified, and is not listed as a CC/MCC in Appendix C part 1. That classification does not mean the illness has no clinical significance, no effect in every risk model, or that another severity tier has necessarily been lost. A more specific diagnosis may leave the final DRG unchanged because of exclusions, other diagnoses, or the grouping pathway.
Other types require their own instructions. Right-sided failure has distinct entries; biventricular failure (I50.82) and end-stage failure (I50.84) have code-also instructions for the known type of left-ventricular or heart failure. They are not an interchangeable set of acute/chronic codes. Do not extend the table's severity classifications to every I50 code or count each description as an independent severity increment.
Hypertension and CKD change the code set
Under FY 2027 I.C.9.a, hypertension and qualifying heart disease, including heart failure, are presumed related unless documentation clearly states they are unrelated. Another possible cause, such as ischemic heart disease, does not by itself establish nonrelationship. Do not demand a separate “hypertensive heart failure” sentence when the classification already supplies the relationship.
When applicable, I11.0 identifies hypertensive heart disease with heart failure, with an additional I50.- code to identify the HF type. If hypertension, qualifying heart disease, and CKD are present with the presumed relationships intact, consider I13 instead. Hypertension with CKD alone is a different pathway, generally I12, rather than automatically I13.
I13.0 describes hypertensive heart and CKD with HF and stage 1–4 or unspecified CKD. Its instructions require additional HF-type and CKD-stage codes.
I13.2 describes the corresponding combination with stage 5 CKD or ESRD, with the specified additional codes.
These are code-set and relative-sequencing instructions, not a declaration that I13 is principal in every hospitalization involving the kidneys or heart. Apply the circumstances of admission, other applicable sequencing rules, and the complete documented conditions. Acute kidney injury is distinct from the CKD stage and may require its own code when reportable.
Worked coding example
An admission is established after study as chiefly for acute-on-chronic systolic HF . The provider also documents hypertension and stage 3 CKD without further subdivision. No documentation indicates nonrelationship, and no competing principal-diagnosis or special sequencing issue applies. The hypertensive heart/CKD combination is represented by I13.0 , with I50.23 and N18.30 as the additional codes identifying HF type/acuity and CKD stage.
The example expressly establishes systolic HF through provider documentation. A record saying only “CHF” with EF 28% does not independently justify inserting I50.23 into the same sequence. Likewise, do not turn stage 3 into 3a or 3b from an isolated laboratory estimate without the required provider diagnosis.
Frame a useful query
For “CHF” with an unclear current phenotype or acuity, present the relevant prior and current assessments, dated testing, symptoms, actual treatment, and competing explanations. Ask about the unresolved element. A fixed menu listing every acute, chronic, and combined variant is not automatically compliant simply because it is long.
Use supported options or an appropriate open-ended format, permit an alternative response, and avoid CC/MCC, reimbursement, or quality-score pressure. A provider may confirm a more specific diagnosis, retain an unspecified description, or identify another cause. Reconcile that response with the record, then apply classification, reportability, and complete grouping separately.
Sources: 2022 AHA/ACC/HFSA official guideline slide set, tables 4 and 6 ; 2023 ACC HFpEF consensus key points ; FY 2027 ICD-10-CM I.C.9.a ; FY 2027 Index and Tabular List, Failure/heart and I50/I13 ; final MS-DRG v44 Appendix C ; 2026 query brief .